Calibr’s research interests span a large range of human diseases, including cancer, autoimmunity and inflammatory diseases, metabolic and cardiovascular diseases, infectious and neglected diseases, as well as age-related and degenerative diseases. Calibr’s research space includes a newly renovated 35,000 square foot facility in La Jolla, CA, which houses over 100 interdisciplinary scientists and staff with state-of-the-art instrumentation. This infrastructure, combined with Calibr’s drug discovery expertise, enables projects rooted in novel therapeutic mechanisms to progress from the laboratory through preclinical development and ultimately to the clinic through commercial, federal or foundation partnerships. Peter G. Schultz serves as the Institute Director and the Institute is governed by an independent Board of Directors. The Institute also receives strategic scientific input from a Scientific Advisory Board chaired by Christopher T. Walsh.
Calibr receives support from foundations, federal and state government, and pharmaceutical industry partners. In 2012, Merck committed up to $90 million over seven years to fund a broadly focused research program, and in exchange Merck has first right to negotiate for an exclusive commercial license to any proteins or small molecule therapeutic candidates.
The Bill & Melinda Gates Foundation awarded Calibr a five-year, $28.9 million grant in 2014 to create a collaborative drug discovery platform focused on diseases of the developing world. Other major grants from the Wellcome Trust, JDRF, GATB, Cure SMA and state and federal agencies have enabled Calibr to accelerate efforts to discover innovative new medicines. In addition, multiple late-stage preclinical projects are under discussion with commercial partners for clinical development; and in the near future the Institute hopes to carry out independent proof of concept clinical studies.
Calibr augments a robust internal research portfolio through collaboration with leaders in the academic research community. As a not for profit, Calibr leverages its ability to readily form partnerships with academic institutions. Calibr currently has over 20 collaborative research projects and is actively seeking out new opportunities of high mutual interest.
Training young scientists in translational research is paramount to the discovery of innovative new medicines in our future. Calibr’s postdoctoral fellow program accepts the best and brightest candidates from multiple disciplines to train in all aspects of drug translational research, while developing their skills in grant writing and encouraging publication in high impact journals. The program equips fellows to tackle major challenges in modern medicine as they move forward in their own independent careers.